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Abstract
Oligomeric Amyloid-β 1–42 (Aβ-42) peptides are considered to be the most toxic species 
connected to the occurrence of Alzheimer’s disease. However, not all aggregation conditions 
promote oligomer formation in vitro, raising the question whether oligomer formation in vivo also 
requires a specific suitable cellular environment. We recently found that interaction with neuronal 
membranes initiates aggregation of Aβ-42 and neuronal uptake. Our data suggest that small 
molecules in the extracellular space can facilitate the formation of membrane-active Aβ-42 
oligomers. We analyzed the early stage of Aβ-42 aggregation in the presence of glucose and 
sucrose and found that these sugars strongly favor Aβ-42 oligomer formation. We characterized 
oligomers by dynamic light scattering, atomic force microscopy, immuno-transmission electron 
microscopy and fluorescence cross correlation spectroscopy. We found that Aβ-42 spontaneously 
and rapidly forms low molecular weight oligomers in the presence of sugars. Slightly acidic pH 
(6.7–7) greatly favors oligomer formation when compared to the extracellular physiological pH 
(7.4). Circular dichroism demonstrated that in presence of crowding agents Aβ-42 oligomers did 
not adopt a β-sheet structure. Unstructured oligomeric Aβ-42 interacted with membrane bilayers 
of giant unilamellar vesicles (GUV) and neuronal model cells, facilitated cellular uptake of Aβ-42, 
and inhibition of mitochondrial activity. Our data therefore suggest that elevated concentrations of 
glucose within the range observed in diabetic individuals (10 mM) facilitate the formation of 
membrane-active Aβ-42 oligomers.
Graphical Abstract
Amyloid-β-42 forms early unstructured oligomers at physiological glucose concentrations, which 
facilitates its cellular uptake and toxicity.
Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disease. It is associated 
with the misfolding and aggregation of the 42 amino acid form of the Amyloid beta (Aβ-42) 
peptide and of the microtubule-associated protein tau 1–3. While Aβ-42 accumulates in the 
brain in the form of fibrillar deposits, oligomeric species of Aβ-42 are strongly implicated in 
AD pathogenesis. Oligomers are assumed to be the cause of neuronal damage and their 
depletion may reduce neurotoxicity 4–7. Aβ-42 and other amyloidogenic proteins can enter 
neurons via endocytic mechanisms 8–10. We recently found that endocytic uptake of Aβ-42 
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and its aggregation are linked 11. The uptake of monomeric Aβ-42 was preceded by 
aggregation of the peptide on the cellular membrane. This suggests that the Aβ-42 peptide 
interacts with the cellular membrane. Crowding of the peptide at the membrane surface may 
initiate amyloid formation 12.
Numerous studies have described the interaction of Aβ-42 peptides with lipid bilayers 13–17. 
However, it is less clear which species of Aβ-42 – monomeric, oligomeric, protofibrillar, or 
fibrillar can interact with membrane bilayers with high affinity 18, 19. Recent observations 
suggest that membrane binding of Aβ-42 may be linked to the formation of early 
oligomers 20, 21. Experimental conditions in early studies of Aβ-42 membrane interaction 
also may have promoted oligomer formation 22–24.
Different types and sizes of Aβ-42 oligomers were identified in vitro 4, 25–27. Aβ-42 
oligomers compromise membrane integrity, which is a possible pathway of 
toxicity 23, 26, 28, 29. However, in the nucleated polymerization mechanism of amyloid 
formation, oligomeric species are only metastable and are not strongly populated at low 
peptide concentrations 30, 31, raising the question which conditions promote the formation of 
Aβ-42 oligomers in vitro and in vivo. We investigated whether components of the 
extracellular medium, specifically glucose, promote formation of membrane active Aβ-42 
species.
Type II diabetes and Alzheimer’s disease are linked epidemiologically 32–34. However, the 
mechanistic basis of this link is not yet clear 35. Both diseases could be linked on the 
cellular, metabolic or molecular level. Specifically, elevated glucose levels might accelerate 
Aβ-42 oligomer formation. Osmolytes can alter protein folding pathways by burying 
hydrophobic residues and thus thermodynamically stabilizing the protein fold 36. Trehalose 
and disaccharides alter Aβ-42 aggregation state and membrane permeabilization 37. It 
should be noted that glucose and sucrose are often used in the formation of membrane model 
systems such as giant unilamellar vesicles (GUV), meaning that they may have played an 
undiscovered role in Aβ-42 membrane interaction.
Aggregation of Aβ-42 into β-sheet rich amyloid fibrils is a multistep process that proceeds 
through oligomeric and multimeric stages. Amyloidiphilic dyes such as Thioflavin T (ThT) 
are frequently used to measure the kinetics of amyloid cross-β sheet formation 38, 39. 
However, ThT is blind to small unstructured oligomers 40. Fluorescence based techniques, 
such as FlAsH labeling, fluorescence self-quenching, and single molecule fluorescence 
techniques have been powerful tools to quantify and characterize the formation of early 
unstructured Aβ-42 oligomers 40–46. We probed if saccharides can directly alter the 
formation of early Aβ-42 oligomers and Aβ-42 membrane interaction. We characterized 
Aβ-42 oligomer formation in the presence of sucrose and glucose by dynamic light 
scattering (DLS), fluorescence cross correlation spectroscopy (FCCS) and immuno-
transmission electron microscopy (TEM). We found that glucose at low millimolar 
concentrations promotes the formation of early, non-β-sheet oligomers of Aβ-42. 
Furthermore, oligomerization is most pronounced in a narrow range of pH between 6.7–7, 
which is lower than the pH of the extracellular space, but matches early endocytic vesicles. 
Aβ-42 oligomers transiently bind to the lipids of membrane bilayers. The same conditions 
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that promoted oligomer formation in vitro also promoted membrane binding, uptake and 
metabolic inhibition in neuronal model cells.
Materials and methods
Preparation of monomers of Aβ-42
Aβ-42 peptide (R. Volkmer, Charité, Berlin) was dissolved in hexafluoro-2-propanol and 
sonicated at room temperature for one hour in a water bath sonicator. After freezing in liquid 
nitrogen, HFIP was removed by lyophilization, and aliquots of the peptide were stored at 
−20 °C. To prepare unlabeled monomer, lyophilized Aβ-42 was dissolved in 10 mM NaOH, 
sonicated for 25 min in cold water bath, filtered through a 0.2 μm and a 30 kD membrane 
filter (Millipore). The monomers were then kept on ice before use. Aβ-42-Hilyte 488 
(Aβ42–488) and Aβ-42-Hilyte 555 (Aβ42–555) labeled Aβ-42 and scrambled sequence 
Aβ-42 (Anaspec) was dissolved in 10mM NaOH and stored at −80°C. Scrambled Aβ was 
labeled with Alexa 488-NHS ester dye as described in 11. Before use, labeled Aβ-42 was 
mixed with unlabeled Aβ-42 and then monomerized by membrane filtration as described 
above. In FCCS experiments without unlabeled Aβ-42, labeled Aβ-42 was dissolved in 3M 
guanidine hydrochloride (GdnHCl) for 10 minute and then diluted into assay buffer to a final 
GdnHCl concentration of 30 mM.
Preparation of Giant unilamellar vesicle (GUV)
DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids; 7.86 mg/ml) stock 
solution (10 μl) in chloroform was mixed with DiD dye (Invitrogen ;0.8 μl, 20 μM) and 
slowly dried onto two platinum wires, 1cm each. The two wires were inserted through the lid 
of a Teflon reaction vessel. The reaction vessel was filled with 230 μl 10% sucrose solutions 
and the container was placed in heating bath at −60°C. The wires were inserted into the 
liquid and a sinus wave AC current was applied at 10 Hz, 1.09–1.11 V for 2 hours. After two 
hours it was switched to 4 Hz, 1.3V for 30 minutes. The vesicles were then collected in a 0.6 
ml Eppendorf tube and used within 2 days.
AFM sample preparation
10 μM freshly monomerised Aβ-42 was incubated in glucose (0, 5, 10 mM) in PBSN (K-
phosphate 8 mM, pH 6.8; NaCl 150 mM) for 15 minutes. 10 μl aliquots of the above 
solutions were placed on a clean, freshly cleaved mica surface. After 10 minutes, the solvent 
was wicked off by filter paper and the mica was washed 4 times with 20 μl of water to 
remove salts and buffer from the sample. Images were obtained using tapping-mode AFM 
(Bruker).
Immuno-TEM grid preparation
Carbon films on 200-mesh copper grids (Ted Pella) were incubated with 5 μl of sample in 
the dark side of the grid for 10 minutes. The sample was wicked off from the grid and the 
grid was incubated with 10 μl 1% BSA in PBS to block any nonspecific binding. After that 
grids were incubated with anti Aβ antibody 6E10 (Signet), 1:100 diluted in PBS solution 
containing 0.1% BSA for 45 minutes. The grid was then washed by 7 drops of PBS buffer. 
After that grid was incubated with secondary anti mouse IgG antibody conjugated to 10 nm 
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diameter gold nanoparticles (Sigma Aldrich) diluted 1:20 in PBS buffer containing 0.1% 
BSA. 45 minutes later the grid was washed by 7 drops of PBS followed by 7 drops of water. 
Finally grids were stained by 2% Uranyl acetate solution for 2 minutes and air dried before 
collecting the images on a FEI Transmission Electron Microscope.
ThT Aggregation kinetics of Aβ-42
Freshly filtered monomeric Aβ-42 was dissolved in PBSN (K-phosphate 8 mM, pH 6.8; 
NaCl 150 mM) containing different concentration of glucose, or in GS buffer (solution of 
190 mM glucose, 100 mM sucrose, 8 mM Potassium phosphate, pH 6.8) containing ThT dye 
(20 μM). Peptides were incubated at room temperature (25°C) or 37°C, with or without 
shaking for 5 second every 10 minutes, as indicated. The excitation and emission 
wavelengths were 420 and 480 nm respectively. The aggregation was monitored in Tecan 
infinite F200 plate reader in non-binding 96-well black wall, clear bottom (Corning 3651) 
plates.
Ultracentrifugation
Monomeric Aβ-42 (100 μl, 100 μM) or fibrillar Aβ-42 (100 μM monomer equivalent) that 
had been pre-incubated in PBSN buffer for 7 days, was incubated in PBSN + 9 mM glucose 
and 1 mM 6-NBDG. After incubation for 3 days at 4°C the solutions were centrifuged at 
70,000 rpm (~200,000 × g) for 20 minutes at 4°C in a TL-100 centrifuge (Beckman). 
Supernatants were collected and pellets were washed with the same volume of PBSN + 10 
mM glucose and centrifuged again. The pellet was dissolved in 100 μl of PBSN + 10 mM 
glucose. Fluorescence spectra of supernatant and pellet fractions were collected in a 
Spectramax i3× plate reader (Molecular Devices) in a 96 well plate with excitation at 474 
nm at 25°C.
Dynamic light scattering (DLS)
Freshly filtered monomeric Aβ-42 was diluted into PBSN buffer (100 μl) with and without 
glucose (5 and 10 mM) in a disposable cuvette (Brand). Scatter intensities were measured in 
triplicate (10 traces of 10 s each) at 25°C, 173° backscatter measurement angle in a Malvern 
Zetasizer Nano ZS instrument with 633 nm laser excitation and a single-photon counting 
avalanche photodiode detector. All solutions were filtered through a 0.2 μm membrane filter 
prior to use. Calculation of correlation functions, cumulant analysis and size distribution 
analysis were performed using the Zetasizer software. The intensity-weighted mean 
diameter was derived from quadratic cumulant analysis. The polydispersity index of Aβ 
oligomers in glucose was below 0.4. Intensity-weighted size distributions were calculated by 
non-negative least squares (NNLS) analysis. Signals from samples without glucose were 
highly polydisperse and were not analyzed quantitatively.
Circular dichroism (CD)
Circular Dichroism (CD) was performed in a 1mm path length quartz cuvette in a Jasco 
J-810 spectropolarimeter. The scan speed was 50 nm / minute, data pitch of 0.5, response 
time 8 second, 5 continuous accumulations for the secondary structure of peptide. The 
scanning range was 190 to 260 nm. Molar ellipticities were calculated by subtracting the 
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ellipticity from the buffer control, and then multiplying by 106 and dividing by 41 and 
concentration of peptide used for the experiment. It should be noted that glucose and sucrose 
have significant positive ellipticities at wavelengths below 205 nm, so care was taken that 
signals stayed in the dynamic range of the CD spectrometer.
Fluorescence cross-correlation spectroscopy (FCCS)
FCCS was measured in a Confocor II (Zeiss) equipped with an Ar-ion laser (30 mW) as well 
as 543 nm (1 mW) and 633 nm (5 mW) He-Ne lasers. Samples were measured in 8 well lab-
tek chambers that were previously coated with 0.1% BSA. Fluorescent Aβ-42 peptides were 
monomerized as described above. 5 sets of data each averaged over 30 seconds were 
collected with 488 nm (Aβ-42-Hilyte 488, Alexa 488) and 543 nm (Aβ-42-Hilyte 555) 
excitation at 50% laser power. In the green channel, the emission filter was a 505–530 nm 
bandpass while in the red channel a 585 nm long pass filter was used. Concentration of 
labeled Aβ-42 was in nanomolar range (10–50 nM). Diffusion data were fitted by one- or 
two-component models of three-dimensional diffusion at a fixed structural parameter κ = 6 
in solution and with a two-dimensional free diffusion model on membranes. Autocorrelation 
data were fitted with triplet correction, cross correlation data without, as described in 47–49. 
The following fitting models were used in the experiments.
3D single component diffusion:
3D single component diffusion with triplet excitation
3D - two component diffusion
Where, 
N is number of particles, T is fraction of intersystem crossing, τD is diffusion time, τt is 
triplet correlation time, κ is structural parameter.
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Z-scan FCS was performed in the Confocor II. The excitation sources were 488 and 633 
lasers. For the green channel (Aβ-42-Hilyte 488) a 505–530 nm band pass filter was used 
while in the red channel (DiD) a 650 nm long pass filter set was used. In order to monitor 
the membrane lipid diffusion, we stained GUV with DiD dye as described above. Aβ-42 
diffusion was measured using Aβ-42-Hilyte 488. First, an immobile GUV was found by 
LSM imaging. Then the GUV of interest was positioned at the center of the laser focus, and 
a z-scan LSM image stack was recorded to confirm that the GUV was not moving. Then, 
cross- and autocorrelation curves were collected starting 4 μm above the GUV surface (bulk) 
at different position along the Z axis - at surface, inside as well as outside of GUV. The 
membrane surface was identified by the fastest diffusion time of the membrane lipid. The 
obtained autocorrelation curves were fitted by 2D one or two component diffusion with 
triplet excitation as indicated in the figures.
2D - two component diffusion with triplet excitation
Calculation of oligomer sizes
Translational diffusion coefficients (D) of the biomolecules were calculated from diffusion 
times (τd):
where, r0 is the laser beam radius, D is the diffusion co-efficient and τD is the diffusion time. 
To calculate r0 a dye with a known diffusion coefficient (Alexa 488) was used. 
Hydrodynamic radii were calculated using the Stokes-Einstein equation:
where, Rh is the hydrodynamic radius, kB is the Boltzmann constant, T is the temperature, 
n0 is the viscosity and D is the diffusion co-efficient of the molecule.
MTT (3–(4,5–dimethylthiazol–2–yl)–2,5–diphenyltetrazolium bromide) assay
SH–EP cells were seeded into 96–well plates (7 k / well), grown to 80% confluency and 
treated with Aβ-42 that had been incubated at 5 μM concentration in PBSN for 2h or 24 h 
with and without 10 mM glucose. Aβ-42 was added to cells at the indicated concentrations 
and incubated for 3 days. MTT (1 mg / ml, 10 μl / well) was added and cells were incubated 
at 37 °C for 4 h. After that solubilization solution (10% Triton X-100, 0.1M HCl in 
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isopropanol, 100 μl / well) was added and incubated for overnight. The absorbance of MTT 
was recorded at 570 nm in a Tecan infinite F200 plate reader.
Aβ-42 uptake into SH-EP cell
Cells were seeded into a 8 well Lab-Tek chamber and grown to 80% confluency. Monomeric 
Aβ-42 (5 μM) was mixed with 0.2 % monomeric Aβ42–488 in PBSN buffer (0, 5, 10 mM 
glucose) for 30 minutes. The formed oligomeric Aβ-42 was diluted to 150 nM in CDMEM 
media and added to the cells. After 24 h incubation, the treated cells were washed twice with 
PBS and fixed with 4 % paraformaldehyde for 15 min at RT. 20 images of cells were 
collected by fluorescence microscopy (488 nm excitation) for each condition. The intensity 
of Aβ inclusions was evaluated in Image J analysis software. The total intensity of Aβ42–
488 fluorescence was measured for each image and the average background fluorescence per 
pixel was subtracted. Plotted is a box plot of corrected fluorescence from 20 images per 
sample. P value was calculated from a two-tailed t-test assuming equal variances.
Silver staining of SDS PAGE gel
Required amount of sample were mixed with loading buffer and boiled at 95°C for 10 
minutes. Then run the gel and after completion, the gel was silver stained by using silver 
staining kit (Sigma Aldrich) according to their provided protocol.
Results
Aβ-42 forms small, unstructured oligomers in the presence of sucrose and glucose
We tested the influence of glucose on Aβ-42 aggregation kinetics through dynamic light 
scattering and Thioflavin T (ThT) fluorescence (Fig. 1A, B). Freshly monomerized Aβ-42 (5 
μM) was incubated in the presence of glucose (0, 5, 10 mM) in PBSN (K-phosphate 8 mM, 
pH 6.8; NaCl 150 mM). While ThT fluorescence revealed no influence of glucose on 
aggregation kinetics (Fig. 1B, Suppl. Fig. S1A, B), DLS revealed that Aβ-42 had formed 
aggregates prior to ThT binding (Fig. 1A). Glucose, at physiological concentration (5 mM) 
and at 10 mM concentration strongly accelerated the formation of Aβ-42 aggregates (Fig. 
1A). When analyzing the hydrodynamic radii of aggregates, we found that in buffer without 
glucose, after 100 minutes the peptide formed large aggregates that were heterogeneous in 
size. In contrast, we found fairly homogenous aggregate populations of Aβ-42 in 10 mM 
glucose (Suppl Fig S2A). The size of these aggregates increased with time (Suppl. Fig. S2B.
We visualized Aβ-42 species by AFM under the same experimental conditions (Fig. 1C). 
Initially, after 15 min incubation, AFM revealed spherical oligomers of 4 ± 1 nm height (Fig. 
1C). Oligomers of similar size were much more abundant in 10 mM glucose than in the 
absence of glucose. In a corresponding experiment, we visualized Aβ-42 structures after 30 
min incubation by TEM and immuno-gold staining using anti-Aβ-42 antibody 6E10 in a 
buffer with physiological osmolarity. This buffer matched conditions in many membrane 
binding experiments (GS buffer, 190 mM glucose, 100 mM sucrose, 8 mM K phosphate, pH 
6.8; Fig 1D). After 30 min, Aβ-42 had formed both small oligomer with diameters of few 
nanometers and larger oligomer structures with an average diameter of 100 ± 50 nm. Initial 
glucose-induced Aβ-42 oligomers remained soluble when analyzed by centrifugation at 
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200,000 × g and SDS-PAGE (Suppl. Fig. S3). These structures transitioned into amyloid 
fibrils after prolonged incubation (Fig. 1D). These data indicate that glucose and sucrose 
accelerate the formation of early Aβ-42 oligomers. Interestingly, glucose increased the 
fraction of SDS-stable Aβ-42 trimers in SDS-PAGE (Suppl. Fig. S3). In previous studies, 
such trimers correlated to Aβ-42 toxicity 4.
We investigated whether Aβ-42 adopted a β-sheet structure in the early oligomers using 
circular dichroism (CD) spectroscopy. Aβ-42 is unstructured as a monomer but adopts a β-
sheet structure in amyloid fibrils50. The minimum at 200 nm, characteristic of unstructured 
polypeptides, was reduced over the course of 60 min incubation, both in the presence and 
absence of glucose / sucrose, indicating minor structural change (Fig. 2A, B). However, no 
β-sheet structures, indicated by a minimum at 218 nm, were formed. Therefore, we conclude 
that glucose-induced oligomers do not possess the cross-β motif that is characteristic for 
amyloid structures. Correspondingly, these structures were invisible in ThT aggregation 
assays since ThT did not bind to Aβ-42 during this phase of aggregation (Fig. 1B).
We then probed whether these early Aβ-42 oligomers bind glucose. To do so, we incubated 
monomeric Aβ-42 (100 μM) with a mixture of the fluorescent glucose analog 6-(N-(7-
Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-Deoxyglucose (6-NBDG, 1 mM) and unlabeled 
glucose (9 mM) in PBSN. The recruitment of 6-NBDG into the pellet was evaluated after 3 
day incubation at 4˚C by ultracentrifugation (200,000 × g). 6-NBDG fluorescence was 
measured in the supernatant and the pellet fractions (Fig. 2C, D). We found that 9% of 6-
NBDG had co-precipitated with Aβ-42 oligomers. In contrast, only residual signals of 6-
NBDG were detected in the pellet fraction when incubated with preformed fibrils (2.4%) 
under the same conditions (Fig. 2D) or in the absence of Aβ-42 (0.2%, Fig. 2D). This 
indicates that glucose binds specifically to early Aβ-42 oligomers with higher affinity than 
to preformed Aβ-42 fibrils.
Glucose can form Schiff base adducts to primary amines, such as lysine side chains, which 
can lead to covalent crosslinking of proteins by advanced glycation end products 
(AGE) 51, 52. We tested for covalent adducts of glucose (10 mM in PBSN) to Aβ-42 (5 μM) 
by MALDI mass spectrometry under the same reaction conditions as above. However, we 
only observed masses corresponding to unmodified Aβ-42 mono-, di-, and trimers (Suppl. 
Fig. S4A–F). Likewise, analysis of Aβ-42 by SDS-PAGE did not reveal any covalent 
crosslinking of peptides (Suppl. Fig. S5). Therefore we conclude that sugar induced Aβ-42 
oligomers without covalently modifying the Aβ-42 peptide. However, since higher-order 
oligomers could not be observed by MALDI, we cannot exclude the possibility that Aβ-42 
forms Schiff base adducts in these structures.
Oligomer formation at nanomolar Aβ-42 concentrations
We utilized the sensitivity of FCCS in order to monitor early oligomer formation at 
micromolar and nanomolar concentrations. We monomerized a fluorescently labeled Aβ42–
488 (16 nM) and Aβ42–555 (16 nM) by GdnHCl treatment. Monomeric Aβ-42 was then 
incubated in GS buffer for 60 minutes and auto- and cross-correlation curves were recorded 
at different time points (Fig. 3A, B). Cross-correlation amplitudes rapidly increased 
indicating the aggregation of Aβ-42 peptides. A plot of normalized cross-correlation 
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amplitudes (NG/NRG, Fig. 3C) vs. time shows that the fraction of Aβ-42 incorporated into 
oligomers increased with time 47–49. At the same time autocorrelation signals indicated a 
decrease in the number of monomeric Aβ-42 molecules as monomers were incorporated into 
aggregates (Fig. 3B). Analysis of the diffusion times of the cross-correlation signal revealed 
rapid formation of small oligomers (τD = 100 ± 7 μs) corresponding to a hydrodynamic 
radius of ~2 nm (Fig. 3D). Similar results were obtained when co-incubating fluorescently 
labeled Aβ-42 (Aβ42–488, 18 nM; Aβ42–555, 25 nM) with unlabeled Aβ-42 (5 μM, Fig. 
3E–H). Here, peptides were monomerized via membrane filtration at pH 10.5, similar to the 
experiments shown in Figs. 1 and 2. However, at micromolar peptide concentrations, larger 
aggregates were detected at incubation times > 30 min (denoted by * in Fig. 3H), 
corresponding to amorphous aggregates visualized by TEM. These aggregates could not be 
adequately be characterized by FCCS. This is most likely due to the inherent bias of 
diffusion-based FCS against relatively rare, large, and slow-moving aggregates 53, 54. In 
contrast to the previous experiment, only weak increase in cross-correlation was observed in 
the absence of sugar (Suppl. Fig. S6A, B). No increase in cross-correlation signal was 
observed when mixing Aβ42–555 with scrambled sequence Aβ42–488 or when mixing dyes 
without Aβ (Suppl. Fig. S6C, D). This indicates that the observed cross-correlation signal 
corresponded to specific oligomer formation.
pH Dependence of glucose-induced oligomer formation
The extracellular space (pH 7.2–7.4), the cytosol (pH 7.0–7.4) and the endocytotic 
compartments (pH 6.0–6.5) offer environments of slightly different acidity 55, which could 
affect Aβ-42 oligomer formation. To test this hypothesis, we measured Aβ-42 
oligomerization in the presence of glucose and sucrose as a function of pH and incubation 
time in the osmolyte buffer (Fig. 4) by FCCS spectroscopy as described in the previous 
section. We found a striking change of the normalized cross-correlation signal within a 
narrow pH range (Fig. 4), indicating that the formation of Aβ-42 oligomers is highly 
dependent on the local pH. We observed maximal oligomer formation at the range of pH 
6.7–6.9, which corresponds to the pH found in early endocytic vesicles 55, 56. This result 
suggests that budding endocytic vesicles on the membrane surface may be the ideal 
environment for Aβ-42 oligomer formation. These oligomers could bind to the membrane 
and aggregate into larger amyloid structures.
Aβ-42 oligomers transiently interact with membrane bilayers
Our next goal was therefore to investigate the binding of Aβ-42 oligomers to membrane 
bilayers. We used giant unilamellar vesicles (GUV) as a membrane model system for single 
molecule binding experiments 57, 58. GUVs of DOPC, labeled with the membrane dye DiD, 
were generated by electro-formation, carefully diluted into GS buffer and settled on a glass 
coverslip (Fig. 5). When adding Aβ-42 (5 μM + Aβ42–555, 50 nM), we found no strong 
enrichment of fluorescently labeled Aβ-42 on the GUV membrane (Suppl Fig. S7), 
suggesting that Aβ-42 might transiently interact with the membrane bilayer. Therefore, we 
took the advantage of Z-scan fluorescence correlation spectroscopy (Z-scan FCS), to 
characterize the membrane interaction of Aβ-42 59, 60.
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We placed the FCS volume 4 μm above the GUV, added Aβ-42 (5 μM + Aβ42–488, 50 nM) 
and moved the focal volume down by steps of 0.2 nm. We used the autocorrelation signal of 
the DiD dye to pinpoint the position of the membrane, which is the z-position at which the 
diffusion time of the membrane marker is minimal and its correlation amplitude is maximal 
(Fig. 5) 59, 60. While performing FCS measurements, we confirmed by repeated confocal 
imaging that the GUV under study was not moving. Fig. 5 shows representative correlation 
curves of Aβ42–488 (left) and DiD (right) recorded above the GUV membrane and on the 
membrane surface.
Figures 6A, B, and C show plots of autocorrelation amplitudes, counts per molecule (cpm), 
and diffusion times of the red and the green fluorescence channel as functions of z-position, 
respectively. Maxima of correlation amplitudes and cpm of the membrane dye combined 
with minima of the diffusion time indicated the membrane position at 246.5 ± 0.2 nm. Since 
Aβ42–488 was present both in the bulk solution and on the membrane, its diffusion time 
increased as the focus was moved into the membrane bilayer, while the count rate per 
molecule dropped to an intermediate level. On the membrane, the average number of Aβ42–
488 molecules in the detection volume increased ten-fold from 30 to 300 and then dropped 
to 0, since no Aβ-42 molecules were present inside the GUV (Fig. 6B). At the same time the 
average diffusion time of Aβ-42 increased from 90 ± 5 μs to 370 ± 200 μs (Fig. 6C), 
indicating that Aβ-42 on the membrane diffused much more slowly than in solution. In 
contrast cpm of the Aβ-42 channel increased only moderately by 40% on the membrane 
when compared to the bulk solution, suggesting that Aβ-42 species in solution and on the 
membrane had similar brightness and therefore contained similar numbers of monomers.
When comparing the membrane dye DiD (1230 ± 110 μs) and Aβ-42 (370 ± 220 μs ; Fig. 
6C) diffusion times corresponded to diffusion constants of 11 μm2s−1 and 28 μm2s−1 
respectively61 on the membrane. We noted that, even though Aβ-42 diffused much more 
slowly on the membrane than in solution, its diffusion time was faster than that of the 
membrane dye. A faster diffusion of Aβ-42 than the lipid dye suggests that Aβ-42 oligomers 
were not incorporated into the membrane but only bound transiently and moved by a 
‘hopping’ mechanism 62.
Glucose induced Aβ oligomers accumulate on neuronal cell membranes
Our in vitro data suggest that glucose facilitate the formation of membrane-active Aβ-42 
species, and may thus accelerate Aβ-42 binding to cellular membranes and its uptake into 
neurons. We tested whether glucose induced oligomers could accumulate on the surfaces of 
cell membranes of neuronal model cells. We incubated Aβ-42 (5 μM + Aβ42–488, 8 nM) 
for 30 min in PBSN (0, 5, 10 mM glucose) and then diluted the Aβ-42 to 150 nM into the 
medium of human neuroblastoma (SH-EP) cells, so that the cells do not experience 
differences in osmolarity in the experiments. At this concentration, SH-EP cells do not 
internalize monomeric Aβ-42 11. After 24 h, we imaged cells by fluorescence microscopy 
and quantified cellular Aβ-42 inclusions via Aβ42–488 fluorescence intensity (Fig. 7A). The 
amount of Aβ-42 found in inclusions correlated with glucose concentration during 
incubation. Glucose-induced Aβ-42 oligomers formed significantly more inclusions than 
Aβ-42 incubated in the absence of glucose (Fig. 7A). These inclusions were partially 
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associated with the cell membrane and partially internalized into the cell. This indicates that 
glucose-induced Aβ-42 oligomers are indeed membrane-active and bind to cellular 
membranes. This furthermore suggests that elevated glucose levels facilitate the formation of 
membrane-active early oligomers and their uptake into neurons. However, we cannot 
exclude the possibility that the glucose that is bound to Aβ oligomers influences the cells 
directly.
Glucose induced Aβ oligomers inhibit mitochondrial activity
Accumulation and uptake of Aβ-42 into neurons are correlated with mitochondrial 
inhibition11. This suggests that the induction of membrane active oligomers by glucose 
could be a first step in Aβ-42 toxicity. We tested whether Aβ-42 oligomers formed in buffers 
with elevated glucose concentration could inhibit mitochondrial metabolism of human 
neuroblastoma (SH-EP) cells by measuring their capacity to reduce the dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Fig. 7B)7, 63. Aβ-42 (5μM) 
was incubated in PBSN + 10 mM glucose for 2 h or 24 h and then added to the medium of 
SH-EP cells. Glucose induced oligomers inhibited MTT reduction significantly more than 
Aβ-42 incubated in PBSN without glucose. These data suggest that elevated glucose may 
accelerate the formation of toxic Aβ-42 oligomers.
Discussion
Aβ-42 oligomers have been identified as a main toxic species in AD 5. Endocytic uptake and 
toxicity of Aβ-42 are tightly linked 8, 9, 11. We found that aggregation of Aβ-42 is a 
prerequisite for its efficient uptake and that Aβ-42 aggregates in a compartment on the cell 
membrane if endocytosis is inhibited 11. This raises the question if monomeric, oligomeric, 
or fibrillar forms of Aβ-42 initially interact with the membrane. This question is not yet 
resolved 18, 64. Aβ-42 monomers can interact with membranes at high concentrations 
through electrostatic interactions 22, 23, however, monomeric Aβ-42 binds to neutral 
membrane bilayers with poor affinity, whereas oligomeric forms of Aβ-42 interact with lipid 
bilayers and bind to cell membranes 11, 18.
We found that Aβ-42 rapidly forms oligomers in the presence of glucose and sucrose at 
nanomolar peptide concentrations. These early oligomers did not bind to ThT and did not 
have β-sheet structure. Oligomer formation occurred at physiological glucose levels in the 
range observed in healthy to diabetic individuals (5 – 10 mM), which raises the possibility 
that oligomers may be the form of Aβ-42 that is present under physiological conditions. 
Alternatively, since glucose concentration in the ISF (interstitial fluid) is about twofold 
lower than in the serum 65, our results raise the possibility that Aβ-42 exists in equilibrium 
between monomers and oligomers that can be shifted towards oligomers in the case of 
hyperglycemia.
Thus, hyperglycemia may provide a mechanistic link between diabetes and Alzheimer’s 
disease. Type 2 diabetes is strongly associated with an increased risk of AD and elevated 
glucose levels accelerate the progression of mild cognitive impairment towards 
dementia34, 66, 67. The link between glucose and Aβ-42 may be twofold: On one hand acute 
hyperglycemia in the blood serum increases both glucose levels in the ISF and Aβ-42 
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levels 65. On the other hand, we find that hyperglycemia accelerates the formation of 
oligomeric species of Aβ-42 that may initiate the pathway towards amyloid formation.
How does glucose effect the oligomerization of Aβ-42? Glucose molecules co-precipitate 
with Aβ-42, if they are present during oligomerization, but not if they are added after mature 
Aβ-42 fibrils have already been formed (Fig. 2C and 2D). This implies that Aβ-42 
oligomers incorporate glucose while Aβ-42 fibrils have a much lower affinity to glucose 
than monomeric or oligomeric Aβ-42. Studies of Aβ-42 amyloid formation in the 1990s 
have observed that extensive glycation of Aβ-42 and other amyloidogenic peptides alters 
their aggregation propensity and may stabilize seeding competent fibrils 6869. This effect 
was attributed to advanced glycation end products (AGE) that covalently modify and 
crosslink Aβ-42 molecules. AGE have been implicated in aging and age-related diseases, 
and specifically in AD and diabetes 7052. AGE form via Maillard reaction at neutral pH in 
the presence of phosphate 52. Modification proceeds via initial Schiff base formation with 
primary amines, such as lysines, followed by structural rearrangement into Amadori 
products 52, 71. Subsequent oxidation and condensation into AGE can be catalyzed by 
transition metal ions 51. While quantitative formation of AGE usually requires incubation 
with molar concentration of glucose at neutral pH for several months, the initial 
modification of Aβ-42 by Schiff base formation with glucose was observed within 24 h or 
less 51. However, our data give no evidence that AGE are formed during early Aβ-42 
aggregation. Rather, they suggest that glycation could exacerbate Aβ-42 toxicity by 
different, previously uncharacterized mechanism, i.e. the induction of membrane-active 
Aβ-42 oligomers.
Conclusions
Our data suggest that elevated concentrations of glucose within the range observed in 
diabetic individuals (10 mM) initiate the formation of mostly disordered, but membrane-
active Aβ-42 oligomers. These oligomers can enter neuronal model cells and inhibit 
mitochondrial activity. Therefore our results suggest that elevated glucose levels can 
exacerbate an early step in Aβ-42 aggregation and toxicity. This effect may link type 2 
diabetes and Alzheimer’s disease on a molecular level.
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(A) Scatter intensity of freshly prepared monomeric Aβ-42 (concentration 10 μM) incubated 
at 25°C in PBSN buffer with 0 mM glucose (blue), 5 mM glucose (green) and 10 mM 
glucose (red) at pH 6.8 obtained from dynamic light scattering. Scatter signals of buffer 
without Aβ was subtracted and intensities were normalized to toluene scatter signals; means 
± SD, n = 3. (B) ThT fluorescence of 10 μM freshly filtered Aβ-42 allowed to aggregate in 
the DLS cuvette under the same conditions as in (A). Samples were collected at different 
time point, diluted 3-fold into same buffer + ThT (20μM). Within 2 hours of incubation no 
ThT positive signal was found. After 2 h the diluted sample was further incubated at 37˚C 
(inset) and ThT-positive aggregates were formed. (C) AFM images of 10 μM freshly filtered 
Aβ-42 incubated for 15 minutes in PBSN buffer containing 0 mM, 5 mM, and 10 mM 
glucose at pH 6.8. Scale bars 100 nm. (D) Immuno TEM images of 5 μM Aβ-42 incubated 
in GS buffer of pH 6.8 after 30 minutes and after 5 day incubation; Scale bars 100 nm.
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(A) Circular dichroism (CD) spectra of 5 μM freshly filtered Aβ-42 (A) in GS buffer (190 
mM glucose, 100 mM sucrose, 8 mM K-phosphate, pH 6.8) and (B) in K-phosphate buffer, 
pH 6.8 at different incubation times (0, 10, and 60 min). Fluorescence spectra of 6-NBDG 
measured in the supernatant (C) and in the washed pellet (D) of 100 μM Aβ-42 oligomer, 
preformed fibrils and buffer control (blank).
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(A) Fluorescence cross correlation signals of monomeric Aβ42-hilyte 488 and Aβ42-hilyte 
555 at 16 nM concentration in GS buffer. The cross-correlation amplitude gradually 
increased over time due to oligomer formation. Plots of (B) total particle numbers in green 
channel and red channel, (C) relative cross-correlation amplitude NG/NRG, and (D) diffusion 
time (τD) vs incubation time for Aβ42–488 and Aβ42–555 in GS buffer (E) Cross-
correlation curve of Aβ42–488 and Aβ42–555 mixed with 5 μM Aβ-42 in GS buffer. (F) (G) 
and (H) particle number, NG/NRG, and diffusion time is plotted against time for Aβ42–488 
and Aβ42–555 in GS buffer with 5 μM Aβ-42. All correlation curves were fitted by a single 
component 3D model, except *, which denotes large aggregate component derived from a 
two-component fit at t = 35 min. All other correlation curves were best fitted by a single 
diffusing component.
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Fluorescence cross correlation was measured for 5 μM freshly filtered monomeric Aβ-42 
with 90 nM concentration of Aβ42–488 and Aβ42–555 in GS buffer of different pH. A plot 
of G(0) vs pH after 60 minute incubation shows that in the pH range 6.8–7.0, Aβ-42 forms 
the maximum number of oligomers. The graph show means ± SD of cross correlation 
amplitudes from quintuplicate measurements.
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Schematic representation of Z-scan FCS performed in DiD labeled GUV in GS buffer 
containing 5 μM Aβ-42 along with 50 nM concentration of monomeric Aβ42–488. The 
focal volume was moved from above the GUV surface (a) to the surface (b) to the inside an 
immobilised GUV (c). Autocorrelation curve above, near the surface and inside of an 
immobilised GUV, for Aβ42–488 and DiD dye, respectively are shown. Dashed lines 
represent fits for 2D diffusion with a single component and triplet excitation.
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Z-scan FCS performed in DiD labeled GUV in GS buffer containing 5 μM Aβ-42 along with 
50 nM concentration of monomeric Aβ42–488 and data were fitted as in Fig. 5. The plots 
show as a function of z-position: (A) G(0), (B) counts per molecule (cpm), and (C) diffusion 
time for Aβ42–488 and DiD dye. The region inside the dotted lines indicates data points 
near the surface of the GUV.
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(A) Intracellular Aβ42–488 fluorescence in SH-EP cells as a function of glucose 
concentration; n = 20. Here, n is the number of images. Each image contained 30–50 cells. 
(B) Mitochondrial activity of SH-EP cells after addition of Aβ-42. Aβ-42 (5 μM) was pre-
incubated for 2h or 24h in PBSN +/− glucose and then added to the cell culture media for 3 
d; n = 5, * p < 0.05. Incubation in the presence of glucose increased cellular uptake and 
mitochondrial inhibition by Aβ-42.
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